Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer
出版年份 2023 全文链接
标题
Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer
作者
关键词
-
出版物
BIODRUGS
Volume 37, Issue 6, Pages 891-899
出版商
Springer Science and Business Media LLC
发表日期
2023-09-25
DOI
10.1007/s40259-023-00624-3
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Survival improvement for patients with metastatic colorectal cancer over twenty years
- (2023) Fadl A. Zeineddine et al. npj Precision Oncology
- Use of Biosimilar Medications in Oncology
- (2022) Zeina Nahleh et al. JCO Oncology Practice
- Implementing and Optimizing Biosimilar Use at Mayo Clinic
- (2022) Chelsee J. Jensen et al. MAYO CLINIC PROCEEDINGS
- Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study
- (2022) Douglas J. Rupert et al. BIODRUGS
- Efficacy and Safety of Bevacizumab Biosimilars Compared With Reference Biologics in Advanced Non-small Cell Lung Cancer or Metastatic Colorectal Cancer Patients: A Network Meta-Analysis
- (2022) Xinyi Xu et al. Frontiers in Pharmacology
- Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis
- (2022) Xian Xiao et al. Translational Cancer Research
- Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial
- (2022) Claire Verschraegen et al. BIODRUGS
- Real‐world use of IBI305 , a bevacizumab biosimilar, in a tertiary caner‐specialized hospital in China
- (2022) Zhe Chen et al. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
- Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications
- (2021) Brian Godman et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey
- (2021) Allison R. Kolbe et al. BIODRUGS
- Retrospective Indication-Matched Cohort Study of Reference Product and Biosimilar: Bevacizumab Versus Bevacizumab-Awwb
- (2021) Jennifer Philippon Booth et al. HOSPITAL PHARMACY
- An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access
- (2021) Natasha B. Leighl et al. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting
- Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System
- (2021) Bharati Bhardwaja et al. BIODRUGS
- Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer
- (2021) Whitney Rhodes et al. Future Oncology
- S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients
- (2021) Veena Shankaran et al. JNCI-Journal of the National Cancer Institute
- Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain
- (2021) Miguel Angel Calleja et al. European Journal of Hospital Pharmacy-Science and Practice
- Financial toxicity in cancer care: origins, impact, and solutions
- (2021) Hannah R Abrams et al. Translational Behavioral Medicine
- Coverage for Biosimilars vs Reference Products Among US Commercial Health Plans
- (2020) James D. Chambers et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Assessing biosimilar education needs among oncology pharmacy practitioners worldwide: An ISOPP membership survey
- (2020) Alexandre Chan et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Cost-effectiveness analyses of breast cancer medications use in developing countries: a systematic review
- (2020) Nour Hisham Al-Ziftawi et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Navigating uncharted waters: Developing a standardized approach for evaluating and implementing biosimilar products at a comprehensive cancer center
- (2020) Mara N Villanueva et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions
- (2020) Charles L Bennett et al. LANCET ONCOLOGY
- Efficacy & Safety of Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Non-small Cell Lung Cancer(MAPLE):A Randomized,Double-blind,Phase 3 Study
- (2019) Nicholas Thatcher et al. CLINICAL CANCER RESEARCH
- Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review
- (2018) Emily Leonard et al. Journal of Managed Care & Specialty Pharmacy
- Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis
- (2016) Tobias Engel Ayer Botrel et al. BMC CANCER
- Use of Bevacizumab in Community Settings: Toxicity Profile and Risk of Hospitalization in Patients With Advanced Non–Small-Cell Lung Cancer
- (2015) Nikki M. Carroll et al. Journal of Oncology Practice
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More